Andreas Calatzis: The Limitations of Monitoring Unfractionated Heparin During ECMO
Andreas Calatzis, Managing Director of Eonis GmbH and Dynabyte GmbH, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Frontiers, adding:
”I am happy to announce that our Perspective article has been published in Frontiers in Medicine.
Together with Prof. Christian Weber, Prof. Kai Zacharowski, and Dr. Marie-Louise Lindner, we discuss the limitations of currently available methods for monitoring unfractionated heparin during ECMO and for detecting residual heparin after heparin reversal in cardiac surgery.
This concerns especially the limitations of the anti-Xa assay, which have been reported in the literature (1-4) but have not yet been fully acknowledged by many research groups.
We conclude that due to insufficient validation in the context of ECMO and cardiac surgery the anti-Xa assay cannot be regarded as a generally accepted reference assay for these uses.
Second, pending appropriately designed comparative studies using samples derived specifically from CPB and / or ECMO patients, different anti-Xa assays cannot be considered interchangeable in these settings.
Third, the impact of dextran sulphate on anti-Xa measurements in cardiac surgery and ECMO requires systematic investigation, particularly in the context of protamine reversal and low residual heparin concentrations.
- Gouin-Thibault I, Mansour A, Hardy M, Guéret P, de Maistre E, Siguret V, Cuker A, Mullier F, Lecompte T. Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points. TH Open. 2024 Oct 17;8(3):e297-e307. doi: 10.1055/a-2359-0987.
- Smahi M, De Pooter N, Hollestelle M et al. Monitoring unfractionated heparin therapy: Lack of standardization of anti‐Xa activity reagents. Journal of Thrombosis and Haemostasis, 18, 2613-2621
- Hardy M, Cabo J, Deliège A et al. Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring. Research and Practice in Thrombosis and Haemostasis, 2023; 7
- Lasne D, Toussaint-Hacquard M, Delassasseigne C et al. Factors Influencing Anti-Xa Assays: A Multicenter Prospective Study in Critically Ill and Noncritically Ill Patients Receiving Unfractionated Heparin. Thromb Haemost. 2023 Dec;123(12):1105-1115. doi: 10.1055/s-0043-1770096.
I highly recommend this excellent review by Isabelle Gouin-Thibault, Adam Cuker, Francois Mullier, Thierry Lecompte et al.”
Title: Monitoring unfractionated heparin in ECMO and cardiac surgery: the search for a valid reference standard
Authors: Christian F. Weber, Kai Zacharowski, Andreas Calatzis, Marie L. Lindner
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026
-
Jul 12, 2026, 06:45Brian O Mahony: Advancing Concizumab Therapy for Hemophilia With Inhibitors at ISTH 2026
-
Jul 12, 2026, 06:42PERT-Guided Patient Selection for Advanced Pulmonary Embolism Therapies